A Dexamethasone-regulated Gene Signature Is Prognostic for Poor Survival in Glioblastoma Patients.

ABSTRACT:

Background

Dexamethasone is reported to induce both tumor-suppressive and tumor-promoting effects. The purpose of this study was to identify the genomic impact of dexamethasone in glioblastoma stem cell (GSC) lines and its prognostic value; furthermore, to identify drugs that can counter these side effects of dexamethasone exposure.

Methods

We utilized 3 independent GSC lines with tumorigenic potential for this study. Whole-genome expression profiling and pathway analyses were done with dexamethasone-exposed and control cells. GSCs were also co-exposed to dexamethasone and temozolomide. Risk scores were calculated for most affected genes, and their associations with survival in The Cancer Genome Atlas and Repository of Molecular Brain Neoplasia Data databases. In silico Conn

SUBMITTER: Luedi MM 

PROVIDER: S-EPMC5143186 | biostudies-literature | 2017 Jan

REPOSITORIES: biostudies-literature